



November 2nd, 2022

ARCALIS Inc.

Arcturus Therapeutics Announces Strategic collaboration with CSL

Arcturus Therapeutics Holdings Inc. (hereafter “Arcturus”), one of the founding shareholders of ARCALIS, today announced the strategic collaboration with CSL Seqirus, the second largest influenza company in the world, to develop and commercialize self-amplifying mRNA vaccines. CSL Seqirus is a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines. CSL Seqirus is part of CSL Limited (ASX:CSL; USOTC:CSLLY).

For further information, please see the Arcturus press release;

<https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-collaboration-csl-develop-and-commercialize>